Author Correction: Evolution of HER2-low expression from primary to recurrent breast cancer
Federica Miglietta(University of Padua), Maria Vittoria Dieci(Istituto Oncologico Veneto), Valentina Guarneri(Istituto Oncologico Veneto), PierFranco Conte(University of Padua), Matteo Fassan(University of Padua), Tommaso Giarratano(Istituto Oncologico Veneto), Michele Bottosso(University of Padua), Marcello Mele(University of Pisa), Ottavia Amato, Gaia Griguolo(University of North Carolina at Chapel Hill), Debora De Bartolo(University of Padua), Elisa Genovesi(University of Padua), Matilde Cacciatore(Ca' Foncello Hospital), Grazia Maria Vernaci(University of Padua)
Cited by 8
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|983
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830